PriceTargets.com logo

Ekso Bionics - EKSO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $115.50
  • Forecasted Upside: 2,737.84%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.07 As of 12/4/2025 05:00 PM ET
▼ -0.35 (-7.92%)

This chart shows the closing price for EKSO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ekso Bionics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EKSO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EKSO

Analyst Price Target is $115.50
▲ +2,737.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ekso Bionics in the last 3 months. The average price target is $115.50, with a high forecast of $225.00 and a low forecast of $6.00. The average price target represents a 2,737.84% upside from the last price of $4.07.

This chart shows the closing price for EKSO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Ekso Bionics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/18/2025HC WainwrightSet TargetBuy ➝ Buy$4.00 ➝ $6.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/6/2025HC WainwrightLower TargetBuy ➝ Buy$2,025.00 ➝ $900.00
3/4/2025Lake Street CapitalLower TargetBuy ➝ Buy$450.00 ➝ $225.00
3/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$2,025.00 ➝ $2,025.00
1/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$2,025.00 ➝ $2,025.00
10/29/2024Lake Street CapitalLower TargetBuy ➝ Buy$562.50 ➝ $450.00
10/29/2024HC WainwrightLower TargetBuy ➝ Buy$2,250.00 ➝ $2,025.00
7/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$2,250.00 ➝ $2,250.00
6/24/2024Lake Street CapitalInitiated CoverageBuy$562.50
4/30/2024HC WainwrightBoost TargetBuy ➝ Buy$2,081.25 ➝ $2,250.00
3/5/2024HC WainwrightLower TargetBuy ➝ Buy$2,250.00 ➝ $2,081.25
1/22/2024HC WainwrightBoost TargetBuy ➝ Buy$2,025.00 ➝ $2,250.00
4/28/2023500.comReiterated RatingReiterates
3/30/2023HC WainwrightReiterated RatingBuy$2,025.00
7/29/2022HC WainwrightLower TargetBuy$2,475.00 ➝ $2,025.00
11/3/2021HC WainwrightReiterated RatingBuy
7/30/2021HC WainwrightReiterated RatingBuy$2,475.00
2/15/2021AegisReiterated RatingBuy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Ekso Bionics logo
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $4.07
Low: $3.50
High: $4.46

50 Day Range

MA: $4.86
Low: $3.87
High: $5.60

52 Week Range

Now: $4.07
Low: $2.73
High: $14.97

Volume

5,468,042 shs

Average Volume

36,086 shs

Market Capitalization

$10.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Ekso Bionics?

The following Wall Street sell-side analysts have issued reports on Ekso Bionics in the last twelve months: HC Wainwright, Lake Street Capital, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for EKSO.

What is the current price target for Ekso Bionics?

0 Wall Street analysts have set twelve-month price targets for Ekso Bionics in the last year. Their average twelve-month price target is $115.50, suggesting a possible upside of 2,737.8%. Lake Street Capital has the highest price target set, predicting EKSO will reach $225.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Ekso Bionics in the next year.
View the latest price targets for EKSO.

What is the current consensus analyst rating for Ekso Bionics?

Ekso Bionics currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EKSO, but not buy more shares or sell existing shares.
View the latest ratings for EKSO.

What other companies compete with Ekso Bionics?

Other companies that are similar to Ekso Bionics include SCHMID Group, Trio-Tech International, Westport Fuel Systems, CVD Equipment and Tungray Technologies. Learn More about companies similar to Ekso Bionics.

How do I contact Ekso Bionics' investor relations team?

Ekso Bionics' physical mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company's listed phone number is (510) 984-1761 and its investor relations email address is [email protected]. The official website for Ekso Bionics is www.eksobionics.com. Learn More about contacing Ekso Bionics investor relations.